Discovering The Potential Therapeutic Benefits of LAMC2 (G3918)

Target Name: LAMC2

NCBI ID: G3918

LAMC2

Discovering The Potential Therapeutic Benefits of LAMC2

LAMC2 (Laminin-convertase 2) is a protein that is expressed in a variety of tissues throughout the body, including bone marrow, fat cells, and the liver. It is a member of the BM600 family of proteins, which are known as bone marrow-derived cell antigens (BMAs). BMAs are a source of antigens that can induce an immune response, making them potential drug targets or biomarkers.

The BM600 family of proteins is characterized by the presence of a single transmembrane domain and a C-terminal tail that is involved in interactions with extracellular matrix (ECM) components. LAMC2 is a 14 kDa protein that is expressed in adult human tissues. It is localized to the periosteum, which is the outermost layer of bone tissue, and is involved in the regulation of bone marrow function.

LAMC2 is involved in the regulation of bone marrow development and maintenance. It is a critical protein for the development and maintenance of normal bone marrow microenvironment, which is essential for the production of functional blood cells. LAMC2 plays a role in the regulation of cell proliferation, differentiation, and apoptosis in the bone marrow. It is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In addition to its role in bone marrow development, LAMC2 is also involved in the regulation of stem cell behavior. It has been shown to play a role in the regulation of stem cell self-renewal and differentiative capacity, as well as the regulation of stem cell plasticity. LAMC2 has also been shown to be involved in the regulation of inflammation, which is a critical aspect of immune response and regulation.

As a potential drug target, LAMC2 is due to its ability to induce an immune response in humans. When LAMC2 is expressed in cell culture, it is able to elicit an immune response that is similar to that of CD4+ T cells. This is thought to be due to the presence of LAMC2 on the cell surface, as well as its ability to interact with intracellular signaling pathways.

In addition to its potential as a drug target, LAMC2 is also a potential biomarker for a variety of diseases. For example, LAMC2 has been shown to be elevated in individuals with rheumatoid arthritis (RA), an autoimmune disorder that causes joint inflammation and pain. It has also been shown to be elevated in individuals with cancer, which may indicate that it is involved in the regulation of cancer cell growth and survival.

Overall, LAMC2 is a protein that is involved in a variety of physiological processes in the body. Its role in bone marrow development and maintenance, as well as its involvement in stem cell behavior and inflammation, makes it a potential drug target or biomarker. Further research is needed to fully understand the function of LAMC2 and its potential as a therapeutic agent.

Protein Name: Laminin Subunit Gamma 2

Functions: Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. Ladsin exerts cell-scattering activity toward a wide variety of cells, including epithelial, endothelial, and fibroblastic cells

The "LAMC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LAMC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets